## AEE: Ameren Corporation - XLU: Utilities

### Executive Summary

No thesis match: MRS_10 0.2% below STRENGTH zone (3.0-6.0%); PEG 2.38 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($97.68)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 9
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. What Ameren (AEE)'s Higher Long-Term EPS Growth Target Means For Shareholders**
- Source: Simply Wall Street | 20260106T184254 | Somewhat-Bullish | Relevance: 100%
- Ameren (AEE) has updated its long-term earnings per share (EPS) growth guidance to 6% to 8% annually from 2025-2029, driven by improved regulation and emerging data center demand. This higher target reinforces the company's regulated utility model and large capital plan, while also focusing attention on whether data center load and regulatory support will materialize as expected. While management expresses confidence, investors should consider the reliance on continued supportive regulation and ambitious data center driven load expectations.

**2. UBS Keeps Buy Rating on Ameren Corporation (AEE)**
- Source: Finviz | 20260105T040754 | Somewhat-Bullish | Relevance: 100%
- UBS has maintained a Buy rating on Ameren Corporation (AEE) while slightly reducing its price objective to $115 from $121. Despite this, Ameren revised its long-term EPS growth guidance to 6% to 8% compound annual rate from 2025 through 2029, driven partly by expected data center growth. The company, a regulated utility in Illinois and Missouri, has seen its stock rise by 12.21% YTD as of December 31, 2025, with analysts recognizing its strong investment opportunities and management's ability to navigate regulatory challenges.

**3. UBS Keeps Buy Rating on Ameren Corporation (AEE)**
- Source: Insider Monkey | 20260104T224229 | Somewhat-Bullish | Relevance: 100%
- UBS has reiterated its Buy rating on Ameren Corporation (AEE) but adjusted its price target to $115 from $121, while Morgan Stanley maintained an Equal Weight rating and lowered its price target to $103. Ameren revised its long-term EPS growth guidance to a 6% to 8% compound annual rate from 2025 through 2029, with predicted 2026 EPS between $5.25 and $5.45. The company operates as a regulated utility in Illinois and Missouri, with Morningstar highlighting improved regulations in Missouri as beneficial for investment opportunities.

**4. A Look At Ameren (AEE) Valuation As New Earnings Growth Outlook And Analyst Targets Emerge**
- Source: Simply Wall Street | 20260105T112814 | Bullish | Relevance: 100%
- Ameren (AEE) has provided new long-term earnings growth guidance of 6% to 8% annually from 2025 through 2029, alongside updated analyst views. The stock is currently trading at $100.86, representing a 10.66% discount to the average analyst price target of $111.62, which is supported by expectations of expanding regulated rate base and constructive regulatory relationships. However, a Discounted Cash Flow (DCF) model suggests Ameren might be overvalued with a fair value of $88.10, highlighting a divergence in valuation perspectives.

**5. UBS Keeps Buy Rating on Ameren Corporation (AEE)**
- Source: Yahoo! Finance Canada | 20260104T173000 | Somewhat-Bullish | Relevance: 100%
- UBS has maintained its Buy rating on Ameren Corporation (AEE) but adjusted its price objective to $115 from $121. The utility company reported revised long-term EPS growth guidance of 6% to 8% annually from 2025 through 2029, with projected 2026 EPS between $5.25 and $5.45. This comes as data centers are expected to drive utility performance, and while regulations in Illinois present challenges, management has effectively navigated them.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-17 | UBS | $115 | $121 | -5% |
| 2025-12-12 | Keybanc | $0 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-17 | UBS | main | Buy |
| 2025-12-12 | Keybanc | down | Sector Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.00M) |
| Sells | 7 ($0.98M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 54.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 13.0% (-1.2%)
- Price (T.Rowe) Assoc: 10.6% (-0.8%)
- Blackrock Inc.: 8.0% (+1.5%)
- T. Rowe Price Invest: 5.7% (+8.1%)
- State Street Corpora: 5.2% (+2.4%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 2.38 elevated, pricing in significant growth expectations. Forward P/E 18.9x stretched relative to 6% growth. Quality metrics strong (margin 16%). Analyst sentiment negative (1 target cuts vs 0 raises). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $27.2B |
| Beta | 0.59 |
| 52W Range | $87.04 - $106.73 |
| Short Interest | 3.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.38 |
| Forward P/E | 18.9 |
| Current P/E | 20.0 |
| YoY Growth | 6.2% |
| EPS Direction | STABLE |

### Technicals

MRS_10 weakening modestly (-0.8% over 5 days). Below STRENGTH zone by 2.8pp (needs >3.0% for momentum thesis). MRS_5 (-0.5%) diverging from MRS_10 - short-term weakness emerging. RSI neutral at 51. OFD pattern: +MTN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.17% (CS: 39) | Neutral |
| RSI_14 | 51.2 | Neutral |
| MACD Histogram | 0.32 | Bullish |
| vs SMA20 | 1.015x | Above |
| vs SMA50 | 0.989x | Below |
| vs SMA200 | 1.008x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $100.62
- **Stop Loss:** $97.68 (2.9% risk)
- **Target:** $103.56 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 374
- **Position Value:** $37,631.88
- **Portfolio %:** 37.63%
- **Risk Dollars:** $1,100.00
- **Risk Per Trade:** 1.10%
- **Modifiers:** L1 110% | L2 100% | Combined 1.10x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_ON (MEDIUM) | 1.10x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*RISK_ON regime with strong participation and low volatility. VIX at 14.75 (6th percentile) with breadth at 63.5% signals healthy risk appetite. Fed dovish expectations and AI/semiconductor momentum are primary drivers, though elevated put/call ratio suggests smart money hedging. Focus on quality growth with awareness of potential complacency.*

### Earnings

**Next:** 2026-02-12 (Est: $0.79)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.11 | $2.35 | +11.4% |
| 2025Q2 | $1.00 | $1.01 | +1.4% |
| 2025Q1 | $1.04 | $1.07 | +2.8% |
| 2024Q4 | $0.80 | $0.77 | -3.2% |

---
*RULE-based L3 | 2026-01-07 08:25 | MRS_10*